NCT00864981View on ClinicalTrials.gov

A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Depression
Interventions
DRUG

Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.

DRUG

WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY